SCHEMBL25369232

SCHEMBL25369232

COCc1cccc(NC(=O)c2csc(C(=O)Nc3cccc(NS(C)(=O)=O)c3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ RCOR1 Q9UKL0 1/20 0.46
▸ DHX9 Q08211 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ POLB P06746 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NFATC1 O95644 1/20 0.42
▸ ROCK1 Q13464 4/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ USP7 Q93009 1/20 0.41
▸ USP47 Q96K76 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543959 1.00 KDM1A (0.46) KDM1AMAOBRCOR1DHX9HPGD
SCHEMBL25368280 0.85 DHX9 (0.53) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL30543946 0.85 DHX9 (0.53) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL25368034 0.83 KMT2A (0.60) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL25369081 0.82 DHX9 (0.48) DHX9GAA
SCHEMBL30543897 0.82 DHX9 (0.48) DHX9GAA
SCHEMBL25368564 0.82 KDM4E (0.48) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL30544027 0.81 ALDH1A1 (0.51) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL25367459 0.81 ALDH1A1 (0.51) DHX9HPGDPOLBALDH1A1SMN1; SMN2
SCHEMBL25368623 0.81 DHX9 (0.50) DHX9HPGDPOLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B KDM1A 1647/4885MAOB 3798/4885RCOR1 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback